Treatment of alopecia areata with diphenylcyclopropenone

J Am Acad Dermatol. 1991 Feb;24(2 Pt 1):253-7. doi: 10.1016/0190-9622(91)70037-3.

Abstract

One hundred thirty-nine patients with severe alopecia areata (the majority with the subtotal, total, or universalis type) were treated with topical immunotherapy (diphenylcyclopropenone). Patients were initially treated unilaterally; the other side of the scalp served as a control. In 50.4% of the patients the response was either excellent (total regrowth) or satisfactory (subtotal regrowth with only a few remaining bald patches). The most frequent side effects were eczematous reactions with blistering, spreading of the induced contact eczema, and sleep disturbances.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Alopecia Areata / therapy*
  • Cyclopropanes / administration & dosage
  • Cyclopropanes / adverse effects
  • Cyclopropanes / therapeutic use*
  • Dermatitis, Contact / etiology
  • Eczema / chemically induced
  • Humans
  • Immunotherapy
  • Recurrence

Substances

  • Cyclopropanes
  • diphenylcyclopropenone